The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | The role of oncolytic virotherapy in treating esophageal cancer
Ken Kato, MD, PhD, National Cancer Center Hospital East, Tokyo, Japan, discusses the role of oncolytic virotherapy in the treatment of esophageal cancer, highlighting its potential as a local therapy that can be combined with chemoradiotherapy to improve local control. Oncolytic virotherapy can be used in conjunction with chemoradiotherapy to enhance treatment outcomes, particularly for locally advanced gastric cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Oncolytic viral is also a local therapy and chemotherapy is a systemic therapy. So we can combine the chemoradiotherapy with oncolytic viral to improve the local control so more than the radiotherapy so next we contacted so a new clinical trial so combined with the chemoradiotherapy with the oncolytic virus for the locally advanced so it’s a gastric cancer question
This transcript is AI-generated...
Oncolytic viral is also a local therapy and chemotherapy is a systemic therapy. So we can combine the chemoradiotherapy with oncolytic viral to improve the local control so more than the radiotherapy so next we contacted so a new clinical trial so combined with the chemoradiotherapy with the oncolytic virus for the locally advanced so it’s a gastric cancer question
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
